Houston cell therapy company launches second-phase clinical trial

fighting cancer

March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston energy tech startup Molecule closes series B funding round

Big Bang

Houston-based energy trading risk management (ETRM) software company Molecule has completed a successful series B round for an undisclosed amount, according to a July 16 release from the company.

The raise was led by Sundance Growth, a California-based software growth equity firm.

Sameer Soleja, founder and CEO of Molecule, said in the release that the funding will allow the company to "double down on product innovation, grow our team, and reach even more markets."

Molecule closed a $12 million Series A round in 2021, led by Houston-based Mercury Fund, and has since seen significant growth. The company, which was founded in 2012, has expanded its customer base across the U.S., U.K., Europe, Canada and South America, according to the release.

Additionally, it has launched two new modules of its software platform. Its Hive module, which debuted in 2022, enables clients to manage their energy portfolio and renewable credits together in one scalable platform. It also introduced Elektra, an add-on for the power market to its platform, which allows for complex power market trading.

"Four years ago, we committed to becoming the leading platform for energy trading," Soleja said in the release. "Today, our customers are managing complex power and renewable portfolios across multiple jurisdictions, all within Molecule.”

Molecule is also known for its data-as-a-lake platform, Bigbang, which enables energy ETRM and commodities trading and risk management (CTRM) customers to automatically import trade data from Molecule and then merge it with various sources to conduct queries and analysis.

“Molecule is doing something very few companies in energy tech have done: combining mission-critical depth with cloud-native, scalable technology,” Christian Stewart, Sundance Growth managing director, added in the statement.

“Sameer and his team have built a platform that’s not only powerful, but user-friendly—a rare combination in enterprise software. We’re thrilled to partner with Molecule as they continue to grow and transform the energy trading and risk management market.”

---

This article originally appeared on EnergyCapitalHTX.com.

Rice University professor earns $550k NSF award for wearable imaging tech​

science supported

Another Houston scientist has won one of the highly competitive National Science Foundation (NSF) CAREER Awards.

Lei Li, an assistant professor of electrical and computer engineering at Rice University, has received a $550,000, five-year grant to develop wearable, hospital-grade medical imaging technology capable of visualizing deep tissue function in real-time, according to the NSF. The CAREER grants are given to "early career faculty members who demonstrate the potential to serve as academic models and leaders in research and education."

“This is about giving people access to powerful diagnostic tools that were once confined to hospitals,” Li said in a news release from Rice. “If we can make imaging affordable, wearable and continuous, we can catch disease earlier and treat it more effectively.”

Li’s research focuses on photoacoustic imaging, which merges light and sound to produce high-resolution images of structures deep inside the body. It relies on pulses of laser light that are absorbed by tissue, leading to a rapid temperature rise. During this process, the heat causes the tissue to expand by a fraction, generating ultrasound waves that travel back to the surface and are detected and converted into an image. The process is known to yield more detailed images without dyes or contrast agents used in some traditional ultrasounds.

However, current photoacoustic systems tend to use a variety of sensors, making them bulky, expensive and impractical. Li and his team are taking a different approach.

Instead of using hundreds of separate sensors, Li and his researchers are developing a method that allows a single sensor to capture the same information via a specially designed encoder. The encoder assigns a unique spatiotemporal signature to each incoming sound wave. A reconstruction algorithm then interprets and decodes the signals.

These advances have the potential to lower the size, cost and power consumption of imaging systems. The researchers believe the device could be used in telemedicine, remote diagnostics and real-time disease monitoring. Li’s lab will also collaborate with clinicians to explore how the miniaturized technology could help monitor cancer treatment and other conditions.

“Reducing the number of detection channels from hundreds to one could shrink these devices from bench-top systems into compact, energy-efficient wearables,” Li said in the release. “That opens the door to continuous health monitoring in daily life—not just in hospitals.”

Amanda Marciel, the William Marsh Rice Trustee Chair of chemical and biomolecular engineering and an assistant professor at Rice, received an NSF CAREER Award last year. Read more here.

Houston Spaceport launches $12M expansion for leading space tech co.

to the moon

Houston will get one step closer to the moon, as the Houston Spaceport at Ellington Airport (EFD) has announced an expansion of the lease for Intuitive Machines, the Houston space tech leader dedicated to furthering lunar exploration.

On July 15, the City of Houston announced passage of Amendment 1, which would add three acres of commercial space for Intuitive Machines at the spaceport and a $12 million infrastructure expansion. Approved by the city council and Mayor John Whitmire, the expansion will include new production, testing and support facilities. The amendment extends the current lease for Intuitive Machines from 20 years to 25 years.

"I want to shout out to Intuitive Machines about everything they’re doing at the Houston Spaceport. It’s exciting to see them expand. We’re starting to reach a critical mass out there — more and more aerospace companies want to be at the Spaceport because that’s where innovation is happening,” said Fred Flinkinger, who represents District E on the Houston City Council. “It’s a great sign of momentum, and we’re proud to have them here in Houston."

Intuitive Machines was the first commercial tenant for the Houston Spaceport when it moved into the facility in August 2016. Founded by Stephen Altemus, Kam Ghaffarian, and Tim Crain in 2013, the company holds three contracts with the National Aeronautics and Space Administration (NASA) to deliver payloads to the lunar surface. In 2023, the company opened its doors in Houston with a 105,572-square-foot Lunar Production and Operations Center that contains research and development labs, clean rooms, mission control centers, and a spacecraft assembly floor.


Intuitive Machines landed Odysseus on the moon in February 2024, the first privately owned soft lunar landing ever and the first soft landing since 1972.

The Houston Spaceport is owned and operated by the City of Houston and Houston Airports, who have an eye of keeping the city a prime name in space exploration. As "Houston" was the first word spoken on the moon when Apollo 11 landed in 1969, lunar exploration in particular has a soft place in the heart of the metropolis formerly known as Space City.

“This agreement reinforces Houston’s leadership in space innovation,” said Jim Szczesniak, director of aviation for Houston Airports. “We’re building infrastructure and supporting the next era of lunar and deep space exploration, right here at Houston Spaceport. This partnership represents the forward-thinking development that fuels job creation and drives long-term economic growth.”
View All Listings